
U.S.-listed shares of French biotech firm Abivax ABVX.PA, ABVX.O rise 32% to $151 premarket after fresh takeover chatter
U.S. pharma giant Eli Lilly LLY.N may bid 15 billion euros ($17.52 billion) for Abivax, nearly double its current market cap, French media reports
Abivax and Eli Lilly did not immediately respond to Reuters requests for comment
Abivax is developing an experimental drug, obefazimod, for the treatment of ulcerative colitis and its CEO has said it could become a widely used product
The first takeover rumors linking Eli Lilly to Abivax surfaced on December 10
ABVX soared 1,749% in 2025
($1 = 0.8560 euros)